Tier 1 — highest

Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway

Marc A Riedl, Andrew Saxon, David Diaz-Sanchez
Clinical Immunology 2009 130(3):244-251

Bibliography

PubMed
PMID 19028145
PubMed Central
PMC2668525
Funding
Supported by NIH/NCRR K12 R011 7611, NIH/NIAID P01 AI050495, NIEHS 5P01ES09581-10, and U.S. EPA grant RD83186101.

Study snapshot

DesignSingle-blind placebo-controlled dose-escalation trial
ModelHealthy adults
Sample65
InterventionStandardized broccoli sprout homogenate prepared from 25 to 200 g broccoli sprouts daily for three days; 200 g alfalfa sprout homogenate served as control
Duration3 days
EndpointsNasal-lavage GSTM1 expression; GSTP1 expression; NQO1 expression; HO-1 expression; Tolerability

What the study showed, in plain terms

This human dose-escalation study showed that broccoli-sprout-derived sulforaphane can increase several Phase II antioxidant-response genes in nasal airway cells, with the strongest induction at the highest tested sprout dose.

Key findings

Expression of GSTM1, GSTP1, NQO1 and HO-1 increased in a dose-dependent pattern, while the alfalfa control did not show the same induction. The intervention was tolerated without significant adverse events in the study.

What this study can and cannot tell us

Short duration and gene-expression endpoints in healthy upper-airway tissue. The study demonstrates biological activity but does not establish prevention or treatment of asthma, COPD, pollution-related disease or other clinical outcomes.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified